Provided by Tiger Trade Technology Pte. Ltd.

Nuvation Bio, Inc.

4.85
-0.0150-0.31%
Volume:4.60M
Turnover:21.78M
Market Cap:1.70B
PE:-11.04
High:4.91
Open:4.80
Low:4.63
Close:4.86
52wk High:9.75
52wk Low:3.36
Shares:351.12M
Float Shares:264.00M
Volume Ratio:0.60
T/O Rate:1.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4387
EPS(LYR):-0.6000
ROE:-47.81%
ROA:-12.36%
PB:6.70
PE(LYR):-8.07

Loading ...

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

THOMSON REUTERS
·
Jul 23

Nuvation Bio's Safusidenib Clinical Program, Ibtrozi Opportunity Create Favorable Setup, RBC Says

MT Newswires Live
·
Jul 23

Nuvation Bio (NUVB) Could Be 48% Undervalued As Safusidenib Data Strengthens Its Case

Simply Wall St.
·
Jul 22

Sector Update: Healthcare

MT Newswires Live
·
Jul 21

U.S. Stocks on the Move-yum Brands, AMD, Nuvation Bio

Reuters
·
Jul 21

RBC looks for Nuvation shares to appreciate as safusidenib data builds

TIPRANKS
·
Jul 20

Nuvation Bio Rises as Brain Cancer Drug Data Spur Expansion of Studies

Reuters
·
Jul 20

Nuvation Bio Posts Corporate Deck Highlighting Ibtrozi ROS1+ NSCLC Launch, Safusidenib IDH1 Glioma Program

Reuters
·
Jul 20

Nuvation Bio announces data from the Phase 2 J201 study

TIPRANKS
·
Jul 20

Nuvation Bio Reports Updated Phase 2 Safusidenib Data, Expands Idh1-mutant Glioma Studies

Reuters
·
Jul 20

Nuvation Bio - Reports 52% Confirmed Objective Response Rate in Phase 2 Safusidenib Study

THOMSON REUTERS
·
Jul 20

Analysts’ Top Healthcare Picks: Argenx Se (ARGX), Nuvation Bio (NUVB)

TIPRANKS
·
Jul 13

Nuvation Bio is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 07

Nuvation Bio Prices Upsized USD 287.5 Million Convertible Senior Notes After Full Greenshoe Exercise

Reuters
·
Jul 07

Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering

THOMSON REUTERS
·
Jul 07

Nuvation Bio Plans Offering of $200 Million Convertible Senior Notes Due 2032

Reuters
·
Jul 01

Nuvation Bio Faces More Predictable Growth Supported by Ibtrozi Frontline Adoption, Wedbush Says

MT Newswires Live
·
Jul 01

Nuvation Bio's Taletrectinib Enters UK Regulatory Review

MT Newswires Live
·
Jun 29

Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-positive Non-small Cell Lung Cancer Validated in the United Kingdom

THOMSON REUTERS
·
Jun 29

Nuvation Bio (NUVB) Completes $250 Million Note Offering, Is The Stock Fully Priced?

Simply Wall St.
·
Jun 28